Protagonist Stock 120%, Fund Outlook and Exit Signals
A hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
A concise checklist to evaluate crypto whitepapers, covering goals, roadmap realism, team capabilities, and risk factors for smarter decisions.
16,547 articlesA hedge fund's sizable exit from Protagonist Therapeutics highlights how insiders and funds shape biotech stock moves...
Ukraine’s drone attacks more have targeted Russia’s energy complex, causing refinery fires and fuel shortages that ec...
Ford and GM reported solid profits driven by SUVs in 2025, but a cloud of EV costs, tariffs and trade policy question...
OpenAI reportedly considers delaying its IPO, placing AI stocks in the spotlight. This guide breaks down the potentia...
The Trade Desk surprised with strong earnings, yet its stock fell. This in-depth analysis breaks down the reasons beh...
A timely look at two Roth conversion advantages highlighted by Dave Ramsey. The piece explains how these perks could ...
NVIDIA just delivered spectacular quarterly results that surpassed expectations and reinforced its leadership in AI c...
A veteran CIO warns that even stellar AI earnings may not keep momentum, suggesting the market is testing whether thi...
When a big holder trims a stake in a robotics and AI ETF, it sparks questions about conviction and risk. This guide b...
Investors are weighing the risks and potential rewards as Netflix prepares for its July earnings. This guide breaks d...
As markets swing in early 2026, three actively-managed ETFs are drawing inflows for steady income and downside protec...
GCC debt markets climbed again this week, with six new issues totaling about $6.8 billion and spreads tightening as i...